567 related articles for article (PubMed ID: 27189459)
1. Shingles (Herpes Zoster) Vaccine (Zostavax(®)): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia.
Keating GM
BioDrugs; 2016 Jun; 30(3):243-54. PubMed ID: 27189459
[TBL] [Abstract][Full Text] [Related]
2. Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years.
Keating GM
Drugs; 2013 Jul; 73(11):1227-44. PubMed ID: 23839657
[TBL] [Abstract][Full Text] [Related]
3. Vaccination: a new option to reduce the burden of herpes zoster.
Mick G
Expert Rev Vaccines; 2010 Mar; 9(3 Suppl):31-5. PubMed ID: 20192716
[TBL] [Abstract][Full Text] [Related]
4. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults.
Sanford M; Keating GM
Drugs Aging; 2010 Feb; 27(2):159-76. PubMed ID: 20104941
[TBL] [Abstract][Full Text] [Related]
5. Herpes zoster subunit vaccine for the prevention of herpes zoster.
Symoniak MR; Farrokh P; Gandhi MA; Slish JC
Am J Health Syst Pharm; 2018 Jun; 75(12):861-869. PubMed ID: 29880523
[TBL] [Abstract][Full Text] [Related]
6. Long-term persistence of zoster vaccine efficacy.
Morrison VA; Johnson GR; Schmader KE; Levin MJ; Zhang JH; Looney DJ; Betts R; Gelb L; Guatelli JC; Harbecke R; Pachucki C; Keay S; Menzies B; Griffin MR; Kauffman CA; Marques A; Toney J; Boardman K; Su SC; Li X; Chan IS; Parrino J; Annunziato P; Oxman MN;
Clin Infect Dis; 2015 Mar; 60(6):900-9. PubMed ID: 25416754
[TBL] [Abstract][Full Text] [Related]
7. Vaccination to prevent herpes zoster in older adults.
Gnann JW
J Pain; 2008 Jan; 9(1 Suppl 1):S31-6. PubMed ID: 18166463
[TBL] [Abstract][Full Text] [Related]
8. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
Pellissier JM; Brisson M; Levin MJ
Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of vaccination against herpes zoster.
de Boer PT; Wilschut JC; Postma MJ
Hum Vaccin Immunother; 2014; 10(7):2048-61. PubMed ID: 25424815
[TBL] [Abstract][Full Text] [Related]
11. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine.
Tseng HF; Lewin B; Hales CM; Sy LS; Harpaz R; Bialek S; Luo Y; Jacobsen SJ; Reddy K; Huang PY; Zhang J; Anand S; Bauer EM; Chang J; Tartof SY
J Infect Dis; 2015 Oct; 212(8):1222-31. PubMed ID: 26038400
[TBL] [Abstract][Full Text] [Related]
12. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.
Marin M; Yawn BP; Hales CM; Wollan PC; Bialek SR; Zhang J; Kurland MJ; Harpaz R
Hum Vaccin Immunother; 2015; 11(5):1157-64. PubMed ID: 25806911
[TBL] [Abstract][Full Text] [Related]
13. Herpes zoster vaccine: clinical trial evidence and implications for medical practice.
Burke MS
J Am Osteopath Assoc; 2007 Mar; 107(3 Suppl 1):S14-8. PubMed ID: 17488883
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.
Kawai K; Preaud E; Baron-Papillon F; Largeron N; Acosta CJ
Vaccine; 2014 Mar; 32(15):1645-53. PubMed ID: 24534737
[TBL] [Abstract][Full Text] [Related]
15. Vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia.
Betts RF
J Am Acad Dermatol; 2007 Dec; 57(6 Suppl):S143-7. PubMed ID: 18021866
[TBL] [Abstract][Full Text] [Related]
16. A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan.
Yaegashi M; Matsui H; Yoshida A; Ban H; Miyazaki R; Oda N; Hattori K; Motomura Y; Usami H; Matsushita H
Vaccine; 2024 Jan; 42(3):464-470. PubMed ID: 38172019
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.
Cunningham AL; Lal H; Kovac M; Chlibek R; Hwang SJ; Díez-Domingo J; Godeaux O; Levin MJ; McElhaney JE; Puig-Barberà J; Vanden Abeele C; Vesikari T; Watanabe D; Zahaf T; Ahonen A; Athan E; Barba-Gomez JF; Campora L; de Looze F; Downey HJ; Ghesquiere W; Gorfinkel I; Korhonen T; Leung E; McNeil SA; Oostvogels L; Rombo L; Smetana J; Weckx L; Yeo W; Heineman TC;
N Engl J Med; 2016 Sep; 375(11):1019-32. PubMed ID: 27626517
[TBL] [Abstract][Full Text] [Related]
18. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
[TBL] [Abstract][Full Text] [Related]
19. Zoster vaccine live for the prevention of shingles in the elderly patient.
Zussman J; Young L
Clin Interv Aging; 2008; 3(2):241-50. PubMed ID: 18686747
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]